Clinical Trial: Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Hepatocellular Carcinoma Non-resectable
Study Type: INTERVENTIONAL
Official Title: Study of the Benefit of Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma (HCC)
Brief Summary:
Currently in France, hepatocellular carcinoma (HCC) represents over 30% of indications of liver transplantation (LT) (# 500 cases/year).Chemoembolization (TACE) is the most commonly used bridge treatment in those patients (estimate 60%).These patients will present with a complete response in only 60 % of the cases (# 180 patients per year in France) and failure in 40 % of the cases (# 120 patients per year in France).A systemic treatment using lenvatinib might provide a benefit in patients presenting with a…
Read more